AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00829153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U Clip
Description: Interuppted nitional clips
Study NCT03793439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial
Description: Tofacitinib 5mg oral table twice daily for 16 weeks
Study NCT03793439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Spirometry testing at baseline, week 4, week 8, week 12, and week 16
Study NCT03793439 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA Sequencing
Description: RNA sequencing test at baseline and week 16
Study NCT03793439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory testing
Description: Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16
Study NCT03793439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Taper corticosteroids starting at week 4
Study NCT03793439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Description: After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
Study NCT01781949 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A: Nontargeted rapid HIV screening
Description: Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
Study NCT01781949 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: B: Enhanced targeted rapid HIV screening
Description: Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS \<30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
Study NCT01781949 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: C: Traditional targeted rapid HIV screening
Description: Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
Study NCT03347149 — intervention group
Intervention type: DEVICE
Intervention: Alarm Advisor Software
Description: Providing advice on alarm limits as part of routine medical care
Study NCT01276821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Epinephrine and Normal Saline (0.9%)
Description: 1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
Study NCT01276821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Epinephrine and Hypertonic Saline (3%)
Description: 1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
Study NCT04022486 — intervention group
Intervention type: OTHER
Intervention: Incidence, management and risk factors of seizure
Description: Incidence of seizure, management (treatment, paraclinical examinations) and risk factors of seizure in children admitted for severe bronchiolitis
Study NCT03576144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162
Description: Multiple rising inhaled doses
Study NCT03576144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple rising inhaled doses
Study NCT05090956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mri
Study NCT04250584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSlpr™
Description: mandibular advancement device
Study NCT04250584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SomnoDent® Classic
Description: mandibular advancement device
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: dosages on one spot and 24h collection
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: dosages
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of sleep apnea syndrome
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrocardiogram
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose tolerance test
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cardiac and abdominal magnetic resonance imaging
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ambulatory blood pressure monitoring
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echotracking
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulse wave velocity
Study NCT01716819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Composition of body mass by Dual x-ray absorptiometry
Study NCT00450580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosamprenavir/ritonavir
Description: Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
Study NCT00450580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosamprenavir/ritonavir
Description: Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
Study NCT00829153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional prolene anastomosis
Description: Continuous prolene anastomosis
Study NCT02749734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subretinal transplantation
Description: Transplant hESC-RPE into subretinal space of patients with macular degeneration
Study NCT02162862 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Counseling
Study NCT02162862 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bupropion-SR
Study NCT01499173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Preparedness Intervention
Description: A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
Study NCT04055805 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observational Analysis
Description: Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
Study NCT03408691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresh fermented dairy drink containing probiotic strain
Description: Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks.
Study NCT03408691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acidified dairy drink without ferment
Description: Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks.
Study NCT01613040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose on Day 1
Study NCT01613040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose on Day 11
Study NCT01613040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Multiple daily low doses of RO4917838 for 10 days
Study NCT01613040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Multiple daily oral high doses of RO4917838 for 10 days
Study NCT01613040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RO4917838 placebo
Description: Oral daily doses of placebo to RO4917838 for 10 days
Study NCT00930202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan (Vaprisol)
Description: Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
Study NCT03197207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dragon and Tiger warring in lifting and thrusting
Description: Tight press slow insert in each acupoint through the superficial,intermediate, deep layer, then tight lifting slow withdraw needle through the deep, intermediate, superficial layer . Two acupoints (GB34, GB39) are manipulation in the process three times each during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.
Study NCT03197207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dragon and Tiger warring in twisting-rotating
Description: When needle insert in each acupoint through the superficial,intermediate, deep layer, within each layer twisting thumb forward nine times, then twisting backward six times. Two acupoints (GB34, GB39) are manipulation in the process during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.
Study NCT02416726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nextseq500 sequencer
Description: The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.
Study NCT01916408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wobenzym plus
Description: 3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
Study NCT01916408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PL 1
Description: 3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
Study NCT00878124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 co treatment
Description: CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
Study NCT00878124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Caps
Description: 3 caps twice a day continuously until pregnant or at the end of the study.
Study NCT00722293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
Study NCT00722293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg
Study NCT00722293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
Study NCT01465581 — intervention group
Intervention type: PROCEDURE
Intervention: Division of the filum terminal
Description: Division of the filum is performed through a 6cm incision over the lumbosacral junction that can be oriented either longitudinally or transversely - to be hidden beneath underclothes or swim wear. A single level laminectomy provides sufficient exposure. The dural opening can be as short as 1cm. Under the microscope the filum is identified visually and separated from lower sacral rootlets with the aid of microelectrode stimulation. When a segment of the filum has been excised and sent for laboratory examination, the dura is closed and reinforced with fibrin glue. The wound is closed in layers, and the patient is kept at bed rest horizontal for 2 nights to discourage CSF fistulization of the wound.
Study NCT00941174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 13C5-Calcium-L-Leucovorin
Description: This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
Study NCT01036360 — intervention group
Intervention type: OTHER
Intervention: metabolic chamber
Description: 20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
Study NCT03407781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BBN-IRDye800CW
Description: PET/NIR fluorescent imaging-guided surgery
Study NCT00452803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
Study NCT04057716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: Participants will be asked to extend their time in bed to 11 hours each night for one week.
Study NCT03650946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ga-68 PSMA PET
Description: Ga-68 PSMA PET
Study NCT00452803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation therapy
Description: Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
Study NCT00452803 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation therapy
Description: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
Study NCT01425385 — intervention group
Intervention type: OTHER
Intervention: Near infrared spectroscopy monitoring
Description: This is an observational study without interventions
Study NCT01425385 — intervention group
Intervention type: OTHER
Intervention: Autoregulation monitoring
Description: There are no interventions in this observational study
Study NCT01742429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor
Study NCT01742429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton pump inhibitor
Study NCT01742429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Study NCT01742429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth subsalicylate
Study NCT01742429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: antibiotic
Study NCT01742429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: antibiotic
Study NCT01742429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic
Study NCT01742429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: antibiotic
Study NCT03713190 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.
Study NCT03713190 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.
Study NCT03713190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance without specific pharmacology principles
Study NCT03258892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive STG
Study NCT03258892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03258892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03584763 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical artery Doppler
Description: Umbilical artery Doppler ultrasound will be performed by most expert sonographer in umbilical artery Doppler at the special care unit, using a 3.5MHz transabdominal probe of SAMSUNG MEDISON, SONOACE R5 ultrasound machine, using the standard protocol of the unit for minimizing the interobserver variations.
Study NCT03584763 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Umbilical artery Doppler
Description: Umbilical artery Doppler ultrasound will be performed by most expert sonographer in umbilical artery Doppler at the special care unit, using a 3.5MHz transabdominal probe of SAMSUNG MEDISON, SONOACE R5 ultrasound machine, using the standard protocol of the unit for minimizing the interobserver variations.
Study NCT02933671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprainguinal fascia iliaca (SIFI) block
Description: An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.
Study NCT01690845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARS
Description: Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
Study NCT04349137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tACS
Description: non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.
Study NCT04349137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tACS
Description: non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.
Study NCT04349137 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham HD-tACS
Description: sham non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS)
Study NCT02582996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
Description: The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
Study NCT02582996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
Study NCT03629301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ID-DPP group
Description: This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.
Study NCT03629301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list Group
Description: This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
Study NCT02933671 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham block
Description: An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
Study NCT02933671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic (numbing drug)
Study NCT02933671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Salt water placebo